Urinalysis is one of the most common examinations in microbiological and chemical laboratories as well as at points of care. In addition to bacterial cultures, the term urinalysis encompasses here most common chemical tests related to diseases of the urinary tract and urine particle counting (urine microscopy).

Several existing documents can be consulted for details on the microbiological examination of urine [1–6]. While quite a few national guidelines covering aspects of urinalysis have also been published [7–9], there is no general international standard or consensus document applicable for, for example, accreditation or validation of new technology available.

Recently, a group chaired by Dr Timo Kouri, Tampere, Finland published the European Guidelines for Urinalysis [10] under the auspices of the European Confederation of Laboratory Medicine (ECLM). The complete text of this supplement is available in electronic form from Taylor & Francis at http://www.tandf.no/sjcli. These guidelines were prepared together with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Working Party on Urinalysis, moderated by Dr Vanya Gant, London, UK, to guarantee the quality of the written guidelines from the microbiological point of view. Several experts from most European countries have also contributed to the review of the draft document. An introduction to the project and the recently published paper for clinical chemists is given elsewhere [11]. This paper aims to introduce the guidelines to European clinical microbiologists.

The ECLM European Urinalysis Guidelines discuss the complete process of clinical urine analysis. They embrace indications for urinalysis at several stages: diagnostic strategies; patient preparation; specimen collection and transport; measurement procedures for chemical, morphologic and microbiological analyses; quality assurance; and transmission of information, i.e. requests and reports.

A stepwise strategy for microbiological urinalysis is also presented (Figure 1). Diagnostic schemes are outlined for symptomatic low-risk patients, symptomatic high-risk patients, and asymptomatic bacteriuria, respectively. Acutely ill patients need an examination with high specificity to reliably demonstrate the presence of bacteria to support an immediate treatment decision, while the rest of the cases can await results from bacterial cultures. A high-performance, high-throughput screening procedure with low false-negative rates would identify true negatives and allow significant reduction in costly and unnecessary urine culture.

The guidelines supply detailed instructions for the collection, preservation and transport of specimens obtained from each patient category, to include patients with indwelling catheters and children. Practical and useful illustrations on specimen collection are presented and offered for implementation at the end of the book (also seen in the website of the project at Tampere University Hospital (http://www.pshp.fi/labnet/EUgroup.htm)). Collection containers, preservation and transport are also discussed.

Detailed methods are presented in four appendices. The authors have chosen to classify diagnostic measurement procedures (methods) hierarchically into four levels of performance based on accuracy of measurement: level 1, rapid procedures such as dipsticks with ordinal scale reporting; level 2, routine (quantitative) procedures in common clinical laboratory use; level 3, qualified comparison procedures; and level 4, primary reference measurement procedures (previously referred to as ‘definitive methods’) that are designed to give the true value of the measurand (analyzed component). In microbiology, no such primary procedures are available.
Table 1 The pathogenicity and frequency of microorganisms in midstream urine

<table>
<thead>
<tr>
<th>Pathogenicity in the urinary tract</th>
<th>Frequency (% of isolates)</th>
<th>A. Common (&gt;10%)</th>
<th>B. Fairly common (1–10%)</th>
<th>C. Uncommon (0.1–1%)</th>
<th>D. Rare (&lt;0.1%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Primary pathogens</td>
<td></td>
<td>E. coli</td>
<td>S. saprophyticus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III. Doubtful pathogens</td>
<td></td>
<td>GBS*, yeast, CNS (others)*</td>
<td>Acinetobacter spp., Pseudomonas spp., Stenotrophomonas maltophilia</td>
<td>A great number of reported cases have been published with exceptional cases of infections caused by other species</td>
<td></td>
</tr>
<tr>
<td>IV. Usually urethral or genital flora*</td>
<td></td>
<td>α-Streptococci, Gardnerella vaginalis, lactobacilli etc.</td>
<td>Bifidobacterium spp., 'diphtheroid' rods etc.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Low concentrations are reported even if they are most likely caused by contamination during specimen collection. Most often isolated from children. GBS, group B streptococci (S. agalactiae). CNS, coagulase-negative staphylococci, urease-forming isolates or isolates found in patients with indwelling catheters have increased significance. No identification and susceptibility testing (only exceptionally, if especially indicated). Reproduced from Kouri T, Fogazzi G, Gant V, Hallander H, Hofmann W, Guder WG, eds. ECLM. European Urinalysis Guidelines. Scand J Clin Lab Invest 2000; 60 (suppl 231): 28, by permission of Taylor & Francis AS.
Procedures for bacterial culture can be outlined at three levels:
1. Level 1, screening procedure. Dipslide culture used to identify negative cultures and significant growth of *Escherichia coli* only.
2. Level 2, routine procedure. One microliter is inoculated on CLED agar (blood agar being an option) and incubated aerobically for 24 h.
3. Level 3, qualified comparison procedure. Ten microliters of urine is inoculated by pipette on CLED agar, hematin agar and blood agar aerobically, and cultured anaerobically in carbon dioxide for 48 h.

The proposal to use a liter-based unit, CFB/L (colony-forming bacteria/L), in reports of bacterial concentration in urine instead of CFU/mL (colony-forming units/mL) is an important step in metrological standardization. The character B instead of U was chosen to avoid confusion between exponentials which might result if only mL volumes were changed to L volumes.

The authors also decided to use a novel classification system for organisms causing urinary tract infections based on criteria of pathogenicity, as developed in Sweden (Table 1).

The first group consists of *E. coli* and *Staphylococcus saprophyticus* causing urinary tract infections in individuals with normal urinary tracts. Secondary pathogenic species often occur in hospital-acquired urinary tract infections. The third and fourth groups refer to doubtful pathogens and urethral or genital flora, respectively. This classification influences the suggested limiting concentration of bacterial colonies justifying identification and susceptibility testing in the laboratory (Table 2).

### Table 2  Suggested limiting concentrations of bacterial colonies justifying identification and susceptibility testing in the laboratory.

<table>
<thead>
<tr>
<th>Symptoms* and specimens</th>
<th>Inoculum, minimum volume</th>
<th>Species typeb</th>
<th>Species number</th>
<th>Significant colony concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CFB/L</td>
</tr>
<tr>
<td><strong>Midstream urine specimen</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes*</td>
<td>1 μL</td>
<td>I</td>
<td>1–2c</td>
<td>10⁶</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>1</td>
<td>10⁷ (women)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>1</td>
<td>10⁷ (men)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>2</td>
<td>10⁸</td>
</tr>
<tr>
<td></td>
<td></td>
<td>II</td>
<td>1</td>
<td>10⁷</td>
</tr>
<tr>
<td>No*</td>
<td>10 μL</td>
<td>I–III</td>
<td>1</td>
<td>10⁸</td>
</tr>
<tr>
<td><strong>Suprapubic aspiration specimen</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes or no</td>
<td>100 μL</td>
<td>I–IV</td>
<td>1–2</td>
<td>10⁴</td>
</tr>
<tr>
<td><strong>Specimen from cystoscopy or single urethral catheterization</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes or no</td>
<td>10 μL</td>
<td>I–III</td>
<td>1–2</td>
<td>10⁵</td>
</tr>
<tr>
<td><strong>Specimen from indwelling catheter</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1 μL</td>
<td>I–III</td>
<td>1–3</td>
<td>10⁷</td>
</tr>
<tr>
<td>No</td>
<td>1 μL</td>
<td>I–III</td>
<td>1</td>
<td>10⁸</td>
</tr>
</tbody>
</table>

*Yes = the patient has symptoms; No = no symptoms, or no information about symptoms. bSuggestive category based on growth characteristics (see Table 1). Species of normal urogenital flora (IV) are examined for susceptibility only if especially indicated. cUsually, only one species is identified and tested for antimicrobial susceptibility if 2–5 similar colonies grow (as locally agreed). Occasionally, two species may be identified for specific patient populations. Three or more species are usually reported as ‘mixed culture’ and considered as contaminants. Susceptibility testing of isolates from midstream urine specimens as well as other detailed strategic decisions need local clinical and microbiological consultation. dA 1-μL loop is practical and sufficient for routine workup. However, in specific patient groups, such as in patients with certain urologic diseases, or in the precise evaluation of patients with simple cystitis, a result at ≥10⁵ CFB/L (10⁷ CFU/mL) and a statistically reliable culture result at ≥10⁶ CFB/L (10⁸ CFU/mL) may be clinically significant. This can only be obtained by using a 10-μL loop. This sensitized culture procedure should be especially requested to avoid extra work and costs caused by routine application of a 10-μL loop for all specimens. Reproduced from Kouri T, Fogazzi G, Gant V, Hallander H, Hofmann W, Guder WG, eds. ECLM. European Urinalysis Guidelines. *Scand J Clin Lab Invest* 2000; 60(suppl 231): 30, by permission of Taylor & Francis AS.© 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, *CMI, 7*, 173–178
concentrations of bacteria justifying identification and susceptibility testing in the laboratory. Other factors taken into consideration for interpretation limits are specimen type, gender, number of isolated species and presence of symptoms. These limits allow diagnosis of urinary tract infections down to $10^6$ CFU/L from midstream urine in both females and males. We give detailed recommendations on cut-offs which take the above-mentioned factors into consideration (Table 2). General screening of asymptomatic individuals should be avoided.

The procedures for bacterial culture mentioned above are described in detail in the microbiological appendix section. In addition, we provide guidance and instructions concerning the minimum criteria for identification of bacteria, serial dilution methods for quantitation, and a level 1 ‘microtiter tray method’ for detecting clear-cut infected urines.

Special attention is also paid to near-patient testing. Bacterial detection by non-culture methods is important in emergency diagnostics, as exemplified by test strips for nitrite and leukocyte esterase describing the performance and limits of these reactions. The technical performance of dipslide culture restricts its use to the exclusion of urinary tract infections, and identification of the primary pathogen *E. coli*.

Methods for particle analysis first define basic and advanced levels of urine particle identification for different clinical practices and laboratories (Table 3). The basic level would be mostly used in general or chemistry laboratories and for general patient

### Table 3 Levels of microscopy differentiation in clinical urinalysis

<table>
<thead>
<tr>
<th>Basic level</th>
<th>Advanced level in addition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Red blood cells</strong></td>
<td>Detailed subclasses of erythrocytes:</td>
</tr>
<tr>
<td></td>
<td>dysmorphic erythrocytes</td>
</tr>
<tr>
<td><strong>White blood cells/granulocytes</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Differentiation of leukocytes:</td>
</tr>
<tr>
<td></td>
<td>Granulocytes, lymphocytes, macrophages (monocytes and eosinophils)</td>
</tr>
<tr>
<td><strong>Epithelial cells</strong></td>
<td>From non-squamous epithelial cells:</td>
</tr>
<tr>
<td>Squamous epithelial cells</td>
<td>squamous epithelial cells</td>
</tr>
<tr>
<td>Non-squamous = small epithelial cells</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renal tubular epithelial cells</td>
</tr>
<tr>
<td></td>
<td>Transitional epithelial cells (superficial and deep)</td>
</tr>
<tr>
<td></td>
<td>Intestinal epithelial cells (occurring after bladder surgery)</td>
</tr>
<tr>
<td></td>
<td>Atypical cells (experienced cytopathologist)</td>
</tr>
<tr>
<td><strong>Casts</strong></td>
<td>From non-hyaline casts:</td>
</tr>
<tr>
<td>Hyaline casts</td>
<td>Erythrocyte, granulocyte casts</td>
</tr>
<tr>
<td>Non-hyaline casts</td>
<td>Renal tubular cell casts</td>
</tr>
<tr>
<td></td>
<td>Hyaline, granular, waxy, fatty casts</td>
</tr>
<tr>
<td></td>
<td>Bacteria and yeast-containing casts</td>
</tr>
<tr>
<td></td>
<td>Hemoglobin and myoglobin casts</td>
</tr>
<tr>
<td></td>
<td>Bilirubin casts</td>
</tr>
<tr>
<td><strong>Bacteria</strong></td>
<td>Gram-staining characteristics of bacteria (microbiology laboratories)</td>
</tr>
<tr>
<td><strong>Yeast</strong></td>
<td><em>Schistosoma haematobium</em></td>
</tr>
<tr>
<td><strong>Trichomonas</strong></td>
<td>(in appropriate geographic locations)</td>
</tr>
<tr>
<td><strong>Spermatozoa</strong></td>
<td>Artefacts and mucus as on the left</td>
</tr>
<tr>
<td><strong>Artefacts (hair, paper and textile fibers, starch, glass) and mucus</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Lipids</strong></td>
<td>Lipids, in addition to droplets:</td>
</tr>
<tr>
<td>Droplets (isolated and aggregated)</td>
<td>Oval fat bodies (lipid-laden tubular cells),</td>
</tr>
<tr>
<td></td>
<td>cholesterol crystals</td>
</tr>
<tr>
<td>Crystals</td>
<td>Additional rare crystals:</td>
</tr>
<tr>
<td>Urate, oxalate (mono- and dihydrated), phosphate and cystine</td>
<td>drugs, cystine, leucine, tyrosine</td>
</tr>
<tr>
<td></td>
<td>2,8-dihydroxyadenine, xanthine</td>
</tr>
</tbody>
</table>

populations. The advanced level comprises a microbiological direction (Gram staining for microbiology laboratories), a nephrologic direction (detection of renal elements, i.e. casts and renal tubular cells), or a cytopathologic direction (detection of atypical epithelial cells and malignancy).

Considerable efforts were made to address the issues of different clinical needs, and we classify routine microscopy techniques into different levels of analytic procedures. Level 1 is suggested to contain screening identification of particles, e.g. by using a microtiter tray method and ordinal scale reporting. Level 2 defines a standardized routine procedure with specific aims, such as: (a) Gram staining for classifying uropathogenic bacteria; (b) standardized urine sediment with supravital staining and/or phase contrast microscopy for precise identification of renal particles; and (c) chamber counting of uncentrifuged urine specimens for accurate counting of red and white blood cells that are partially lost during centrifugation. Level 3 should contain sensitive detection and accurate quantitation of clinically significant urine particles. If bacteria only are considered, the slide centrifugation and Gram-staining technique is recommended because of its proven performance against culture. Thus, general (chemical), microbiological and nephrologic needs for urinalysis may differ, and must be taken into account when specifying routine analytic processes.

A chapter on quality assurance gives an extensive discussion on general issues such as quality system, quality manual, and quality policy, as well as very specific matters. Analytic quality specifications are suggested for clinical microbiology laboratories, to help assessment of performance. We suggest (for example) acceptable routine levels of identification for bacteria, and acceptable turnaround times for bacterial cultures. Detail for evaluation of performance of urinalysis devices is provided as a suggestive framework.

This document will be most valuable for persons responsible for analysis of urine in clinical chemistry laboratories and in clinical microbiology laboratories. Acceptance and endorsement of the proposed procedures would be a step towards standardization of urinalysis. This would be of great benefit to laboratories and patients alike.

REFERENCES


APPENDIX, LIST OF CONTRIBUTORS TO THE ECLM EUROPEAN URINALYSIS GUIDELINES


Members of the ECLM European Urinalysis Group

Dr Timo Kouri (Chairman)
Center of Laboratory Medicine
Tampere University Hospital
PO Box 2000, FIN-33521 Tampere
Finland
Tel: +358 3 247 5484 Fax: +358 3247 5554
E-mail: Timo.Kouri@tays.fi

Dr Giovanni Fogazzi
Divisione di Nefrologia e Dialisi
Ospedale Maggiore, IRCCS
Via Commenda 15, I-20122 Milano
Italy
Tel: +39 02 5503 4557 Fax: +39 02 55034550
E-mail: croff1@polic.cilea.it

Dr Vanya Gant
Department of Clinical Microbiology
University College Hospital
Grafton Way, London WC1E 6DB
UK
Tel: +44 171 380 9913 Fax: +44 171 388 8514
E-mail: v.gant@academic.uclh.nthames.nhs.uk

Dr Giovanni Fogazzi
Divisione di Nefrologia e Dialisi
Ospedale Maggiore, IRCCS
Via Commenda 15, I-20122 Milano
Italy
Tel: +39 02 5503 4557 Fax: +39 02 55034550
E-mail: croff1@polic.cilea.it

Dr Vanya Gant
Department of Clinical Microbiology
University College Hospital
Grafton Way, London WC1E 6DB
UK
Tel: +44 171 380 9913 Fax: +44 171 388 8514
E-mail: v.gant@academic.uclh.nthames.nhs.uk

© 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 173–178
Dr Hans Hallander  
Swedish Institute for Infectious Disease Control  
Department of Quality Assurance  
SE-17182 Solna  
Sweden  
Tel: +46 8 457 2490 Fax: +46 83025 66  
E-mail: hans.hallander@smi.ki.se

Dr Walter Hofmann  
Institute for Clinical Chemistry  
Städtisches Krankenhaus Bogenhausen  
Englschalkinger Strasse 77  
D-81925 Munich  
Germany  
Tel: +49 89 9270 2282 Fax: +49 89 92702113  
E-mail: Hofmann-Sedlmier@t-online.de

Professor Dr Walter G. Guder  
Institute for Clinical Chemistry  
Städtisches Krankenhaus Bogenhausen  
Englschalkinger Strasse 77  
D-81925 Munich  
Germany  
Tel: +49 89 9270 2280 Fax: +49 89 92702113  
E-mail: w.g.guder@lrz-muenchen.de

ESCMID Working Party on Urinalysis
Vanya Gant, London, UK, Moderator  
Hans Hallander, Stockholm, Sweden  
Francis O’Grady, Nottingham, UK  
Marc Struelens, Brussels, Belgium

Other contributors
Amores C., Jaen, Spain  
Anyszek Tomasz, Krakow, Poland  
Arnadottir M., Reykjavik, Iceland  
Aspevall O., Huddinge, Sweden  
Baerheim A., Bergen, Norway/Gent, Belgium  
Béné M.-C., Nancy, France  
Blaseio U., Hamburg, Germany  
Blondiau R., Erembodegem, Belgium  
Bondarenko I., St Petersburg, Russia  
Colombo J.P., Bern, Switzerland  
Delanghe J., Gent, Belgium  
Dybkær R., Copenhagen, Denmark  
Edel H., Munich, Germany  
Emanuel V., St Petersburg, Russia  
Fang-Kirchner S., Vienna, Austria  
Fenili D., Romano di Lombardia, Italy  
Fernandes B., Toronto, Canada  
Fuellemann R., Mannheim, Germany  
Garcia J.L., Sevilla, Spain  
Gatermann S., Bochum, Germany  
Grubb A., Lund, Sweden  
Györy A.Z., Sydney, Australia  
Hessie A., Bonn, Germany  
Hoeiby N., Copenhagen, Denmark  
Hofgärtner W., Oxford, UK  
Hyloft-Petersen Per, Odense, Denmark  
Ito K., Yokohama, Japan  
Itoh Y., Osaka, Japan  
Ivandic M., Munich, Germany  
Kermes K., Tartu, Estonia  
Khorovskaya L., St Petersburg, Russia  
Kimling H., Mannheim, Germany  
Kokot F., Katowice, Poland  
Konttainen S., Helsinki, Finland  
Katochvila J., Nymburk, Czech Republic  
Kutter D., Junglinster, Luxembourg  
Lapin A., Vienna, Austria  
Lipsic T., Bratislava, Slovak Republic  
Malakhov V., Moscow, Russia  
Naber K.G., Straubing, Germany  
Naegle U., Mannheim, Germany  
Newall R., Newbury, UK  
Newman D.J., London, UK  
Parker D., Elkhart, IN, USA  
Peheim E., Bern, Switzerland  
Penev M.N., Sofia, Bulgaria  
Piemont Y., Strasbourg, France  
Ponticelli C., Milano, Italy  
Price C., London, UK  
Puglia M., Elkhart, IN, USA  
Rada F., Tirana, Albania  
Recio F., Sevilla, Spain  
Rowan R.M., Glasgow, UK  
Rowlands T., Meylan, France  
Salum T., Tartu, Estonia  
Sandberg S., Bergen, Norway  
Selgren S., Elkhart, IN, USA  
Siitonen A., Helsinki, Finland  
Sikirica M., Zagreb, Croatia  
Steinhaussen R., Mannheim, Germany  
Tetz V., St Petersburg, Russia  
Tzontcheva A., Sofia, Bulgaria  
Verhaegen J., Leuven, Belgium  
Zaman Z., Leuven, Belgium

© 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 173–178